Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1 to 10 of 2245 total matches.

Tirzepatide (Mounjaro) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes ...
The FDA has approved tirzepatide (Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):105-7 | Show Introduction Hide Introduction

Daridorexant (Quviviq) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
) and lemborexant (Dayvigo) were approved earlier.1,2 Pronunciation Key Daridorexant: da ree” doe rek’ sant ...
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):107-10 | Show Introduction Hide Introduction

COVID-19 Update: Pfizer/BioNTech and Moderna Vaccines Authorized for Children ≥6 Months Old

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
was authorized for use in adults ≥18 years old.1 CLINICAL STUDIES — Expansion of the EUAs of both vaccines ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use in children as young as 6 months old. The Pfizer vaccine was previously authorized for use in persons ≥5 years old, and the Moderna vaccine was authorized for use in adults ≥18 years old.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):110-2 | Show Introduction Hide Introduction

COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld)

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
in patients who have experienced a hypersensitivity reaction to a COVID-19 vaccine.1,2 Evusheld contains ...
The labeling for the investigational, long-acting, prophylactic anti-SARS-CoV-2 monoclonal antibodies tixagevimab and cilgavimab (Evusheld; available under an FDA Emergency Use Authorization) now includes warnings about a risk of serious hypersensitivity reactions, including anaphylaxis, with use of the drugs, particularly in patients who have experienced a hypersensitivity reaction to a COVID-19 vaccine.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):112 | Show Introduction Hide Introduction

Drugs for Sexually Transmitted Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022  (Issue 1653)
of the indications and dosages recommended here have not been approved by the FDA (see Table 1). PARTNER TREATMENT ...
This article includes recommendations for management of most sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA (see Table 1).
Med Lett Drugs Ther. 2022 Jun 27;64(1653):97-104 | Show Introduction Hide Introduction

Tapinarof Cream (Vtama) for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jun 22, 2022  (Issue 5049)
' uh The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor ...
The FDA has approved Vtama (Dermavant), a 1% cream formulation of the aryl hydrocarbon receptor (AhR) agonist tapinarof, for treatment of adults with plaque psoriasis. It is the first AhR agonist to be approved by the FDA.
Med Lett Drugs Ther. 2022 Jun 22;64(5049):1-3 | Show Introduction Hide Introduction

COVID-19 Update: Booster Dose of the Pfizer Vaccine for Children 5-11 Years Old

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
of the Pfizer vaccine ≥5 months previously.1 IMMUNOGENICITY – Expansion of the EUA was based on the results ...
The FDA has expanded its Emergency Use Authorization for the mRNA COVID-19 vaccine manufactured by Pfizer/BioNTech (Comirnaty) to include administration of a booster dose in children 5-11 years old who completed a primary series of the Pfizer vaccine ≥5 months previously.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):94 | Show Introduction Hide Introduction

COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
a contraindication.1,2 The EUA was revised because of the risk of thrombosis with thrombocytopenia syndrome (TTS ...
The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) are preferred for all persons without a contraindication.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):94-5 | Show Introduction Hide Introduction

COVID-19 Update: NIH Recommends Against Ivermectin

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
are available.1 IVERMECTIN – Ivermectin has been used for years for treatment of infections caused ...
On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled trials of ivermectin have produced negative results and because alternative drugs that have been shown to be effective for treatment of COVID-19 are available.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):95-6 | Show Introduction Hide Introduction

COVID-19 Update: Remdesivir (Veklury) FDA-Approved for Children <12 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
and are either hospitalized or at high risk for progression to severe disease.1 Remdesivir was already FDA ...
IV antiviral drug remdesivir (Veklury) has now been FDA-approved for treatment of COVID-19 in patients ≥28 days old who weigh ≥3 kg and are either hospitalized or at high risk for progression to severe disease. Remdesivir was already FDA-approved for these indications in patients ≥12 years old who weigh ≥40 kg; it was available under an Emergency Use Authorization (EUA) for younger or lighter patients. Remdesivir is the first drug to be FDA-approved for treatment of COVID-19 in children <12 years old.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):e1 | Show Introduction Hide Introduction